[REDACTED]

Overview

The company has a new, innovative respiratory drug and needs strategic counsel to overcome regulatory, market access outside of China, and policy challenges. Our team determined the project's success is defined by the drug's smooth entry into neighboring markets, its ability to compete with domestic and international players, and the establishment of a sustainable long-term presence in China. I remapped our focuses from pharmaceutical distributors to leveraging The Asia Group's expertise in policy advocacy, government relations, and market strategy to create a favorable operating environment for the client.

Objectives

Advocate with the NMPA for priority review to shorten the drug's approval timeline
Formulate a plan to get the drug on the NRDL, ensuring patient access and profitability
Identify and build relationships with Chinese companies and government bodies to strengthen the client's market position
Develop a strategy to protect the drug's patents and trade secrets from unauthorized use
Provide guidance on adhering to China's strict data security and privacy laws
Engage with Chinese officials to advocate for policies favorable to local medicines
Build the client's public image as a trusted provider of high-quality medicines
Continuously track changes in healthcare policies and market trends for a proactive response

Project Details

Category:
Biopharmaceutical
Client:
[Redacted]
Year:
2023

← Back to Works